Abstract: The present invention relates to bioactive extracts its fractions and isolation of compound from Rauwolfia tetraphylla. The extracts and fractions are useful for the treatment of psychosis based on in-vivo validation on animal model and proportional binding affinities for dopaminergic-D2, Cholinergic (muscarinic) and Serotonergic (5HT2A) receptors for antipsychotic activity. The present invention relates to novel antipsychotic activity in the leaf alkaloids of Formula 1 and 2 named tetrahydroalstonine, 10-methoxytetrahydroalstonine, isoreserpiline, 10-demethoxyreserpiline, 11-demethoxyreserpiline, reserpiline and ?-yohimbine. The present invention also relates to processes for obtaining antipsychotic extracts as well as for the isolation of alkaloids of formula 1 and 2 from the leaves of Rauwolfia tetraphylla. The present invention particularly relates to significant antipsychotic activity in the MeOH extract, ethylacetate and chloroform fractions of R.

Abstract: The present invention relates to bioactive extracts its fractions and isolation of compound from Rauwolfia tetraphylla. The extracts and fractions are useful for the treatment of psychosis based on in-vivo validation on animal model and proportional binding affinities for dopaminergic-D2, Cholinergic (muscarinic) and Serotonergic (5HT2A) receptors for antipsychotic activity. The present invention relates to novel antipsychotic activity in the leaf alkaloids of Formula 1 and 2 named tetrahydroalstonine, 10-methoxytetrahydroalstonine, isoreserpiline, 10-der?ethoxyreserpiline, 11-demethoxyreserpiline, reserpiline and ?-yohimbine. The present invention also relates to processes for obtaining antipsychotic extracts as well as for the isolation of alkabids of formula 1 and 2 from the leaves of Rauwolfia tetraphylla. The present invention particularly relates to significant antipsychotic activity in the MeOH extract, ethylacetate and chloroform fractions of R.

Abstract: The present invention provides an improved preparation based on the synergistic action of garlic extract and essential oil of M. spicata var. Ganga or cinnamon oil against dermatophytic fungus. More particularly, the present invention relates to the synergistic enhancement of activity of a combination by menthyl acetate or Geraniol. The invention also provides a method of preparation of the synergistic combination and the shelf life observed to be more than one year. The cream based preparation is a potent anti-dermatophytic as described and illustrated by in vitro and in vivo evaluations.

Abstract: An in vitro screening method for identifying insect tolerant genotypes or clones is described. The method comprises growing plantlets in an in vitro system, screening the plantlets for molecular variation of somaclones using RAPD analysis in vitro, selecting the somaclones having molecular variation, exposing the somaclones to insect larvae or nymphs and identifying the surviving somaclones.

Abstract: The present invention relates to a method of testing Bacopa monnieri response to abiotic stress factors and for testing bioactivity of natural, synthetic and semisynthetic compounds using Bacopa monnieri plant, which comprises growing the said plant and plant parts aseptically in MS 0 basal medium with agar in microcentrifuge tubes by adding the compounds to be tested either to the culture media or by spraying the said compounds on the plant or plant parts or on the said medium to detect the distinct morphological and cytological responses.

Abstract: The present invention relates to the new use of an already known biomolecule methyl-?-orcinol carboxylate of formula I isolated from a lichen (Everniastrum cirrhatum), for treating pathogenic fungal infections of humans that are resistant to polyene and azole antibiotics such as amphotericin B, nystatin, clotrimazole etc.

Abstract: The present invention provides an improved preparation based on the synergistic action of garlic extract and essential oil of M. spicata var. Ganga or cinnamon oil against dermatophytic fungus. More particularly, the present invention relates to the synergistic enhancement of activity of a combination by menthyl acetate or Geraniol. The invention also provides a method of preparation of the synergistic combination and the shelf life observed to be more than one year. The cream based preparation is a potent anti-dermatophytic as described and illustrated by in vitro and in vivo evaluations.

Abstract: The present invention relates to the development of a novel multiutility vigorously growing robust mint plant ‘Ganga’ of Mentha spicata L. var. viridis producing essential oil exhibiting anti-insect and anti-microbial activities and useful for agrochemical and pharmaceutical purposes.

Abstract: The present invention relates to a novel nitrile glycoside of Formula I named NIAZIRIDIN and to analogues and derivatives thereof. The present invention also relates to a process for the isolation of a novel nitrile glycoside of Formula I below named NIAZIRIDIN and its derivatives and analogues by bioactivity-guided fractionation from the pods of Moringa oleifera. The present invention particularly relates to the bioenhancing activity of the novel nitrile glycoside of Formula I below named NIAZIRIDIN and its derivatives and analogues in enhancing bioactivity of commonly used antibiotics such as rifampicin, tetracycline and ampicillin against Gram (+) and (?) bacteria. The biomolecule also enhances the absorption of drugs, vitamins and nutrients through the gastro-intestinal membrane increasing their bio-availability. Therefore niaziridin can be used in combination therapy with drugs and nutrients resulting in reduced drug associated toxicity, reduced cost and duration of chemotherapy.

Abstract: A formulation useful in the treatment of drug resistant bacterial infections comprising an effective amount of thymol obtained from the plant Trachyspermum ammi, mint oil containing an appropriate amount of monoterpenes obtained from a hybrid of Mentha spicata and Mentha arvensis, and conventional additives. A method for producing the formulation by mixing the above ingredients and a method for the treatment of drug resistance in a patient by administration of a therapeutically effective amount of the formulation.

Abstract: The present invention relates to a novel nitrile glycoside of Formula I named NIAZIRIDIN and to analogues and derivatives thereof. The present invention also relates to a process for the isolation of a novel nitrile glycoside of Formula I below named NIAZIRIDIN and its derivatives and analogues by bioactivity-guided fractionation from the pods of Moringa oleifera. The present invention particularly relates to the bioenhancing activity of the novel nitrile glycoside of Formula I below named NIAZIRIDIN and its derivatives and analogues in enhancing bioactivity of commonly used antibiotics such as rifampicin, tetracycline and ampicillin against Gram (+) and (−) bacteria. The biomolecule also enhances the absorption of drugs, vitamins and nutrients through the gastro-intestinal membrane increasing their bio-availability. Therefore niaziridin can be used in combination therapy with drugs and nutrients resulting in reduced drug associated toxicity, reduced cost and duration of chemotherapy.

Abstract: The present invention relates to the new use of an already known biomolecule methyl-&bgr;-orcinol carboxylate of formula 1 isolated from a lichen (Everniastrum cirrhatum), for treating pathogenic fungal infections of humans that are resistant to polyene and azole antibiotics such as amphotericin B, nystatin, clotrimazole etc.

Abstract: The present invention relates to a method of testing Bacopa monnieri response to abiotic stress factors and for testing bioactivity of natural, synthetic and semisynthetic compounds using Bacopa monnieri plant, which comprises growing the said plant and plant parts aseptically in MS 0 basal medium with agar in microcentrifuge tubes by adding the compounds to be tested either to the culture media or by spraying the said compounds on the plant or plant parts or on the said medium to detect the distinct morphological and cytological responses.

Abstract: A formulation useful in the treatment of drug resistant bacterial infections comprising an effective amount of thymol obtained from the plant Trachyspermum ammi, mint oil containing an appropriate amount of monoterpenes obtained from a hybrid of Mentha spicata and Mentha arvensis, and conventional additives. A method for producing the formulation by mixing the above ingredients and a method for the treatment of drug resistance in a patient by administration of a therapeutically effective amount of the formulation.

Abstract: A formulation useful in the treatment of drug resistant bacterial infections comprising an effective amount of thymol obtained from the plant Trachyspermum ammi, mint oil containing an appropriate amount of monoterpenes obtained from a hybrid of Mentha spicata and Mentha arvensis, and conventional additives. A method for producing the formulation by mixing the above ingredients and a method for the treatment of drug resistance in a patient by administration of a therapeutically effective amount of the formulation.

Abstract: This invention is related to the development of strategic and novel composition comprising &agr; arteether and nalidixic acid or quinolone drugs, said composition useful as an advanced generation drug to counter the resistance development itself and having a potential to be used in treating infectious diseases and in inhibiting the resistance developed due to mutation in the gyr A gene of bacteria, particularly in those cases where drug resistant strains are known to appear very frequently.

Abstract: The invention provides a rapid in vitro method for selection of menthol rich mint genotypes from a large population of independent clones, said method comprising the steps of (i) raising a heterogeneous population of Mentha arvensis clones in vitro or by vegetative methods, (ii) transferring the plantlets/shoots to a basal medium, containing cytotoxic compounds in an amount sufficient to cause toxic effect in more than 95% of the clones, (iii) selecting surviving clones, their hardening in the glasshouse, transfer to field, reconfirmation of menthol tolerance through repeated in vitro assays, and (iv) multiplying selected clones and confirming genetic uniformity through RAPD analysis.

Abstract: The present invention is related to a method of producing organogenetic tissues from a plant of the genus Mentha, said method comprising the steps of culturing an explant from a plant of genus Mentha on an initiation medium in the presence of 400 to 600 lux light at a temperature of 23-27° C., with 16 hours of photoperiod, to obtain calli, transferring the calli to a basal medium comprising minerals and vitamins to ensure development of shoots, and culturing the shoots in a medium substantially free of growth hormones and containing menthol in a concentration of about 80 &mgr;g ml−1 to ensure root formation.

Abstract: The present invention relates to the development of a novel multiutility vigorously growing robust mint plant ‘Ganga’ of Mentha spicata L. var. viridis producing essential oil exhibiting anti-insect and anti-microbial activities and useful for agrochemical and pharmaceutical purposes.

Abstract: The present invention relates to a novel, insect tolerant, high yielding essential oil and menthol yielding mint plant named ‘Sambhav’, which is a cultivar of Mentha arvensis L.. The mint plant of the present invention has been developed as a result of planned experiments which devised a procedure for early selection of somaclonal variants at the in vitro stage of the variety of Mentha arvensis.